Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | FAAH | O00519 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL906353 | 0.74 | — | — | |
| SCHEMBL4061442 | 0.72 | — | — | |
| SCHEMBL10337342 | 0.70 | — | — | |
| SCHEMBL2250254 | 0.69 | ALDH1A1 (0.48) | ALDH1A1TSHRSMN1; SMN2MAPTKMT2A | |
| SCHEMBL3505660 | 0.69 | FAAH (0.59) | ALDH1A1TSHRSMN1; SMN2MAPTKMT2A | |
| SCHEMBL13834579 | 0.68 | — | — | |
| SCHEMBL31386 | 0.68 | — | — | |
| SCHEMBL10380003 | 0.67 | ALDH1A1 (0.52) | ALDH1A1TSHRSMN1; SMN2MAPTKMT2A | |
| SCHEMBL3762474 | 0.67 | TSHR (0.43) | ALDH1A1TSHRSMN1; SMN2MAPTKMT2A | |
| SCHEMBL9298897 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7642278-B2 | Nitrogen compounds such as 3-(5-morpholin-4-yl-1H-benz-imidazol-2-yl)-1H-indazole and/or isomers, used as immunology modulators, antidiabetic agents, antiogenesis inhibitors or for prophylaxis of Alzheimer's disease | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2010-01-05 | — | — | US | claimed |
| US-7064215-B2 | Indazole benzimidazole compounds | CHIRON CORPORATION (US) | 2006-06-20 | — | — | US | claimed |
| US-20060079564-A1 | Indazole benzimidazole compounds | CHIRON CORPORATION | 2006-04-13 | — | — | US | claimed |
| EP-1401831-A1 | INDAZOLE BENZIMIDAZOLE COMPOUNDS AS TYROSINE AND SERINE/THREONINE KINASE INHIBITORS | CHIRON CORPORATION (US) | 2004-03-31 | — | — | EP | claimed |
| US-20030207883-A1 | Indazole benzimidazole compounds | CHIRON CORPORATION | 2003-11-06 | — | — | US | claimed |
| WO-2003004488-A1 | INDAZOLE BENZIMIDAZOLE COMPOUNDS AS TYROSINE AND SERINE/THREONINE KINASE INHIBITORS | CHIRON CORPORATION (US) | 2003-01-16 | — | — | WO | claimed |
| US-10405539-B2 | Composition | THE UNIVERSITY OF QUEENSLAND (AU) | 2019-09-10 | — | — | US | disclosed |
| US-20180177185-A1 | COMPOSITION | THE UNIVERSITY OF QUEENSLAND (AU) | 2018-06-28 | — | — | US | disclosed |
| EP-3322295-A1 | COMPOSITION | The University of Queensland (AU) | 2018-05-23 | — | — | EP | disclosed |
| WO-2016201523-A1 | COMPOSITION | THE UNIVERSITY OF QUEENSLAND (AU) | 2016-12-22 | — | — | WO | disclosed |
| US-7642278-B2 | Nitrogen compounds such as 3-(5-morpholin-4-yl-1H-benz-imidazol-2-yl)-1H-indazole and/or isomers, used as immunology modulators, antidiabetic agents, antiogenesis inhibitors or for prophylaxis of Alzheimer's disease | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2010-01-05 | — | — | US | disclosed |
| US-20070185013-A1 | Use of chk1 inhibitors to control cell proliferation | ICOS CORPORATION (US) | 2007-08-09 | — | — | US | disclosed |
| US-7064215-B2 | Indazole benzimidazole compounds | CHIRON CORPORATION (US) | 2006-06-20 | — | — | US | disclosed |
| US-20060079564-A1 | Indazole benzimidazole compounds | CHIRON CORPORATION | 2006-04-13 | — | — | US | disclosed |
| EP-1401831-A1 | INDAZOLE BENZIMIDAZOLE COMPOUNDS AS TYROSINE AND SERINE/THREONINE KINASE INHIBITORS | CHIRON CORPORATION (US) | 2004-03-31 | — | — | EP | disclosed |
| US-20030207883-A1 | Indazole benzimidazole compounds | CHIRON CORPORATION | 2003-11-06 | — | — | US | disclosed |
| WO-2003004488-A1 | INDAZOLE BENZIMIDAZOLE COMPOUNDS AS TYROSINE AND SERINE/THREONINE KINASE INHIBITORS | CHIRON CORPORATION (US) | 2003-01-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060079564-A1 | Indazole benzimidazole compounds | ABL1, ABL2, ALK | ALDH1A1 1562/4885TSHR 4110/4885SMN1; SMN2 1141/4885 |
| US-20180177185-A1 | COMPOSITION | EXOSC9, EXOSC5, AGO2 | ALDH1A1 4118/4885TSHR 3980/4885SMN1; SMN2 1061/4885 |
| US-20070185013-A1 | Use of chk1 inhibitors to control cell proliferation | CHEK1, CHEK2, CDC25C | ALDH1A1 3604/4885TSHR 3502/4885SMN1; SMN2 2983/4885 |
| US-10405539-B2 | Composition | EXOSC9, EXOSC5, AGO2 | ALDH1A1 4118/4885TSHR 3980/4885SMN1; SMN2 1061/4885 |
| US-20030207883-A1 | Indazole benzimidazole compounds | SLCO1B3, SLCO1B1, SLCO4C1 | ALDH1A1 618/4885TSHR 3919/4885SMN1; SMN2 2958/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.